surpass 6 tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Overview of the SURPASS clinical

Its being pitched for metabolic disease, blood sugar control, and weight loss

The most common side effects are gastrointestinal issues, including stomach pain, constipation, nausea, vomiting, and diarrhea

Clinics (Sao Paulo)

If the main mechanism by which GLP-1 medications help fibromyalgia is through weight loss, this could matter, but individual responses to both medications vary considerably

Within the GLP-1 receptor agonist class , other options available in the UK include: Dulaglutide (Trulicity) weekly injection with proven cardiovascular benefits [12] [17] Liraglutide (Victoza) daily injection with proven cardiovascular benefits [13] Exenatide (Byetta) twice-daily injection Exenatide extended-release (Bydureon) weekly injection Lixisenatide (Lyxumia) daily injection Tirzepatide (Mounjaro) weekly injection that acts on both GLP-1 and GIP receptors [14] [15] Whilst these medications share similar mechanisms to semaglutide, individual tolerability varies